If all patients are enrolled by the end of 2024 or early 202 Theralase intends to enroll and treat 100 to 125 patients in approximately 20 clinical sites across Canada and the United States, with its sights set on addressing a multi-billion-dollar unmet need in the global bladder cancer market to lower morbidity and mortality, and improve quality of life.
If all patients are enrolled by the end of 2024 or early 2025, the company believes it can complete primary patient follow-ups by mid-2026, positioning Ruvidar for potential Health Canada and FDA approval by the end of 2026 or early 2027.
Cancer-fighting pharma stock eyes 2027 regulatory approval | 2024-05-02 | Investing News | Stockhouse